



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم



# شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



**MONA MAGHRABY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



### يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**MONA MAGHRABY**



# THE DIAGNOSTIC VALUE OF CA19.9 IN PREDICTING THE RESECTABILITY OF PANCREATIC CANCER

*A Thesis*  
*Submitted for the partial fulfillment of*  
*master Degree in*  
**GENERAL SURGERY**

**BY**  
***Ahmed Ibrahim Ali Ibrahim***


**M.B.B.CH FACULTY OF MEDICINE SOHAG UNIVERSITY**

*Under supervision of*  
**Prof. Dr. Abdelghany Mahmoud Elshamy**  
**Professor of General Surgery**  
**Faculty of Medicine - Ain Shams University**


**Dr. Mohamed Abd Elsttar Abd Elhamid**  
**Lecturer of General Surgery**  
**Faculty of Medicine - Ain Shams University**

**Faculty of Medicine**  
**Ain Shams University**  
**2020**





"وَمَا أُوتِيتُمْ مِّنَ الْعِلْمِ إِلَّا قَلِيلًا"



(ايه ٥٨ من سوره الاسراء)

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# Acknowledgments

First of all, thanks **GOD**, the merciful, the beneficent for helping me during this work.

I would like to express my indebtedness and deepest gratitude to **Prof. Dr. Abdelghany Mahmoud Elshamy**, Professor of General Surgery, Faculty of Medicine, *Ain Shams* University for his valuable advice, guidance and constructive criticism, also for the invaluable assistance and efforts he devoted in the supervision of this study.

I'll never forget, how co-operative was. **Dr. Mohamed Abd Elsttar Abd Elhamid**, Lecturer of General Surgery, Faculty of Medicine, *Ain Shams* University, also he was encouraging all the time. It is honorable to be supervised by him.

I would like to thank all the staff members of the General Surgery department.

Finally, I would like to express my appreciation and gratitude to all my family, especially my caring and loving parents who enlighten my life.

 **Ahmed Ibrahim Ali Ibrahim**

# Contents

Title	Page
<i>List of abbreviations</i>	<i>I</i>
<i>List of tables</i>	<i>II</i>
<i>List of figures</i>	<i>III</i>
<i>Introduction</i>	<i>1</i>
<i>Aim of the Work</i>	<i>3</i>
<i>Review of Literature</i>	<i>4</i>
• <i>Chapter 1: Anatomy of the pancreas</i>	<i>4</i>
• <i>Introduction</i>	<i>4</i>
• <i>Structure</i>	<i>5</i>
• <i>Shape</i>	<i>6</i>
• <i>Blood supply</i>	<i>8</i>
• <i>Micro anatomy</i>	<i>9</i>
• <i>Variation</i>	<i>11</i>
• <i>Development</i>	<i>12</i>
• <i>Gene and protein expression</i>	<i>13</i>
• <i>Chapter 2: Physiology of the pancreas</i>	<i>14</i>
• <i>Chapter 3: Pathology and epidemiology of pancreatic tumors</i>	<i>18</i>
• <i>Chapter 4: Management Of Pancreatic Cancer</i>	<i>34</i>
• <i>introduction</i>	<i>34</i>
• <i>diagnosis</i>	<i>35</i>
• <i>staging</i>	<i>44</i>
• <i>treatment</i>	<i>55</i>
• <i>prevention</i>	<i>65</i>
• <i>life style modification</i>	<i>66</i>
• <i>Chapter 5: Tumor Marker And Diagnostic Value Of Ca19.9 In Predicting The Resectability Of Pancreatic Cancer</i>	<i>67</i>
<u><i>Tumor marker</i></u>	
• <i>Introduction</i>	<i>67</i>

<ul style="list-style-type: none"> <li>• <i>uses and advantages</i></li> <li>• <i>advantages of using tumour markers</i></li> <li>• <i>disadvantages of using tumour markers</i></li> <li>• <i>examples of tumours markers</i></li> <li>• <i>precautions</i></li> <li>• <i>future scope of tumour markers</i></li> </ul>	68 69 69 70 70 72
<u><i>Tumor marker in pancreatic cancer</i></u> <ul style="list-style-type: none"> <li>• <i>Introduction</i></li> <li>• <i>CA19.9 as a marker for pancreatic cancer</i></li> <li>• <i>Diagnostic value of ca 19.9 in predicting</i></li> </ul>	72 72 73 78
<i>Patients and methods</i>	79
<i>Results</i>	85
<i>Discussion</i>	123
<i>Conclusion</i>	131
<i>Summary</i>	132
<i>References</i>	134
<i>Arabic Summary</i>	٢-١



## List of abbreviations

<b>AJCC</b>	American joint committee on cancer
<b>ALT</b>	Alanine transferase
<b>AST</b>	Aspartate aminotransferase
<b>CA</b>	celiac axis
<b>CA19.9</b>	Carbohydrate antigen 19.9
<b>CBD</b>	Common Bile Duct
<b>CCK</b>	Cytokines
<b>CCK20</b>	Cytokines 20
<b>CCRT</b>	Concurrent chemo radiation therapy
<b>CEA</b>	Carcino-embryonic antigen
<b>cm</b>	Centimeter
<b>CMIA</b>	Chemiluminescent microparticle immunoassays
<b>CT scan</b>	Computed tomography
<b>Direct.bil</b>	Direct bilirubin
<b>EIPC</b>	European institute of pancreatic cancer
<b>ECLIA</b>	electrochemiluminescence
<b>ERCP</b>	Endoscopic Retrograde Cholangiopancreatography
<b>EUS</b>	Endoscopic ultrasound
<b>FDG</b>	Fludeoxyglucose
<b>GOFL</b>	Gemcitabine oxaliplatin Fluorouracil lucoverin
<b>HPF</b>	High power field
<b>IPMN</b>	Intrapapillary mucinous neoplasms
<b>IRB</b>	Institutional research board
<b>I.V</b>	Intravenous
<b>IQR</b>	Inter-quartile range
<b>LAPC</b>	Local advanced pancreatic cancer
<b>M</b>	Mean
<b>MCNs</b>	Mucinous cystic neoplasms
<b>MRCP</b>	Magnetic resonance cholangiopancreatography
<b>MRI</b>	Magnetic resonance imaging

<b>N</b>	Number
<b>NCCN</b>	The national cancer comprehensive network
<b>NICE</b>	National institute for health and care excellence
<b>Pan Nets</b>	Pancreatic neuro-endocrine tumors
<b>PD</b>	Pancreatic Duct
<b>PDAC</b>	Pancreatic ductal adenocarcinoma
<b>PNLIP</b>	Pancreatic lipase
<b>PET</b>	Positron emission tomography
<b>PP.CELLS</b>	Pancreatic polypeptide cells
<b>PTs</b>	Patients
<b>ROR2</b>	RTK-like orphan receptors
<b>RLU</b>	Relative light unit
<b>SD</b>	Standard deviation
<b>SMA</b>	Superior mesenteric artery
<b>SMV-PV</b>	Superior mesenteric vein – portal vein
<b>SMV</b>	Superior mesenteric vein
<b>SPSS</b>	Statistical package for the social sciences
<b>TPA</b>	Tri propyl amine
<b>T.BIL</b>	Total bilirubin
<b>T.N.M</b>	The tumor –lymph node ,metastasis classification
<b>TNM</b>	The tumor node metastasis
<b>UICC</b>	Union for international cancer control

## List of tables

Table	Table of Review	Page
(1)	TNM classification for pancreatic cancer	50
(2)	TNM Staging of pancreatic cancer	51
(3)	Md Anderson cancer center clinical/radiological staging of pancreatic cancer	53
(4)	Show that the age of the study ranged from 28 to less than 88 years	85
(5)	Sex of the patients 16 patients are male and 9 patients are female	86
(6)	Shows locations of the tumors in all patients	87
(7)	Show types of operations in patients with pancreatic cancer	88
(8)	Pancreatic cancer classification according to C.T pancreatic protocol	89
(9)	Show borderline pancreatic tumors after surgery	90
(10)	Show pancreatic tumors classification according to its operability	91
(11)	Show operable pancreatic cancer	92
(12)	Show non –operable pancreatic cancer	93
(13)	Relationships between CA19.9 and its operability	95
(14)	Comparison between CA19.9 ,total ,direct bilirubin and liver enzymes in studied groups	98
(15)	Shows laboratory parameters in operable and non –operable pancreatic cancer	100
(16)	Laboratory parameters of all patients	101

## List of Figures

Figure	Fig. of Review	Page
(1)	Anatomy of Pancreas	4
(2)	Structure of pancreas	5
(3)	Blood supply of pancreas	8
(4)	Micro anatomy of pancreas	9
(5)	Micro anatomy of pancreas	9
(6)	The pancreas originates from the foregut, a precursor tube to part of the digestive tract, as a dorsal and ventral bud, as it develops the ventral bud rotates to the other side and the two buds fuse together	12
(7)	Pancreatic ductal adenocarcinoma (PDA) demonstrating well differentiated glands with significant nuclear atypical infiltrating the stroma (400x)	19
(8)	Mucinous cystic neoplasm (M C N ) of the pancreas with Tall columnar epithelium with intracytoplasmic apical Mucin (100x)	22
(9)	Intraductal Papillary Mucinous (IPMN) of the pancreas demonstrating Intraductal proliferation of Mucin producing cells(100x)	23
(10)	Pancreatic neuro-endocrine tumor with organoid histological pattern and characterized by nesting , the nucleus has coarsely clumped chromatin (100x)	25
(11)	Solid pseudo papillary neoplasm forming pseudo papillae and having poorly cohesive cells between fibro-vascular stalks (100x)	26
(12)	Acinar cell carcinoma of the pancreas demonstrating monotonous cells with eosinophilic and granular cytoplasmic due to zymogenes granules (400x)	27
(13)	Pancreatic cancer mortality in men A and women B globocan 2012 estimate 1- country with the lowest mortality rate 2- country with the highest Mortality rate	29

<b>Figure</b>	<b>Fig. of Review</b>	<b>Page</b>
(14)	Jaundice can be a symptoms due to biliary obstruction from pancreatic tumor	35
(15)	Cross section of a human liver at autopsy , showing many large pale tumor deposits ,that are secondary tumors derived from pancreatic cancer	38
(16)	(The head , body and tails of pancreas , the is faded out in this image to show the entire pancreas , of which the body and tail lie behind the stomach and the neck partially behind	39
(17)	(Axial CT image with I.V. contrast and added color , cross lines toward top left surround a macrocytic adenocarcinoma of the patient head	39
(18)	Abdominal ultrasonography of pancreatic cancer presumably adenocarcinoma ) with dilated pancreatic duct to the right	40
(19)	PET/ CT OF Pancreatic cancer	44
(20)	Stage T1 pancreatic cancer	46
(21)	Stage T2 pancreatic cancer	46
(22)	Stage T3 pancreatic cancer	47
(23)	Stage T4 pancreatic cancer	47
(24)	Pancreatic cancer in nearby lymph node stage N 1	48
(25)	Pancreatic cancer metastasis stage M1	48
(26)	Resectable pancreatic cancer 2008 the university of texas MD Anderson cancer center	53
(27)	Borderline resectable pancreatic cancer 2008 , the university of Texas MD Anderson cancer center	54
(28)	Locally advanced pancreatic cancer (2008)the university of Texas MD Anderson center	54
(29)	(The pancreas , stomach and bowel are joined back together after pancreaticoduodenectomy	56
(30)	Tissue removed during pancreaticoduodenectomy (Whipple's operation )	57
(31)	The process of carcinogenesis showing opportunities of identifying biomarkers	67



<b>Figure</b>	<b>Fig. of Review</b>	<b>Page</b>
(32)	Show the study distribution of the age	85
(33)	Show sex distribution between studied patients	86
(34)	Show locations of the tumors	87
(35)	Types of operations in patients with pancreatic cancers	88
(36)	Showing pancreatic cancer classifications according to C.T pancreatic protocol	89
(37)	Showing borderline pancreatic tumors after surgery	90
(38)	Showing pancreatic tumors according to its operability	91
(39)	Showing operable pancreatic tumor	92
(40)	Showing non –operable pancreatic cancer	93
(41)	Showing relationships between CA19.9 and its operability	95
(42)	Showing comparison between CA19.9 ,total, direct bilirubin and liver enzymes in the five studied groups	99
(43)	Shows laboratory parameters of all patients	101
(44)	Show C.T and PET scan of pancreatic cancer	102
(45)	Show 59 years old male patient with pancreatic cancer (A) PET /C.T fusion (e) Image show a mass in the pancreatic head with increased FDG uptake (arrow)	102
(46)	C.T scan with pancreatic protocol ;show mass of the head of the pancreas	103
(47)	MRI and MRCP for diagnosis and staging of pancreatic cancer	104
(48)	Exploratory laparotomy and distal pancreatectomy	105
(49)	Total pancreatectomy	105
( 50)	Endoscopy and laparoscopy for palliative treatment of local advanced cancer head of pancreas with malignant obstructive jaundice and duodenal obstruction	105
(51)	ERCP with extraction of an obstructed plastic stent with development of partially covered metallic stent for biliary drainage for a patient with pancreatic head cancer with obstructive jaundice	106

Figure	Fig. of Review	Page
(52)	Near total distal pancreatectomy with splenectomy for treatment of large pancreatic body tumor infiltrating the splenic vessels , the head of pancreas was preserved	107
(53)	Reconstruction after resection during whipple' s operation for treatment of pancreatic head cancer	108
(54)	Pancreaticoduodenectomy starting reconstruction with pancreaticojejunostomy	109
(55)	PET/CT for pancreatic cancer	110
(56)	CT with pancreatic protocol ;showing resectable borderline pancreatic cancer	111
(57)	MRI of the adenocarcinoma of the pancreas	111
(58)	CT abdomen with pancreatic protocol ;showing A- Pancreatic head mass encased to CA and SMA >180 degree and the tumor size was 4 cm B- After 2 months there is induction of GOFLtherapy ,the tumor size decreased to 3.6 cm C- After completion of CCRT with GEMICITABINE therapy, the level of CA19.9 decreased to 362 u/ml and the tumor size decreased to 3.2 cm D- After completion of GOFL therapy ,the level of CA19.9 decreased to 62 u/ml and the tumor size decreased to 2.9 cm and the SMA not abutted	112
(59)	CT axial showing primary tumor mass in the tail of the pancreas and multiple liver metastasis	113
(60)	CT abdomen show; a small 2 cm pancreatic adenocarcinoma causing obstruction of both CBD and PD	114
(61)	A- Axial PET/CT image through the pancreatic body and neck regions reveals on FDG-avid lesion in the midline (arrow ),no distant metastatic lesion were detected ,but there is abnormal less FDG –avid activity extending toward the gastric antrum B-MRCP image demonstrates focal narrowing of the main pancreatic duct (arrow) in the region of the mass ,with upstream dilatation in the body and tail C- pancreatic parenchymal phase 5mm axial image	115